The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality

Not Applicable

Recruiting

• Conditions: GLP - 1; Bowel Preparation for Colonoscopy
• Interventions: Drug: Continue GLP/GIP

• Registration Number: NCT07127354
• Lead Sponsor: The Cleveland Clinic

Brief Summary

The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies. The main questions it aims to answer are:

* Does GLP-1 and GIP agonist increase the rate of inadequate bowel preparation?

* Does the quality of bowel preparation differ in patients who hold vs. those who continue a single dose of their GLP-1 or GIP agonist medication?

* Are there any differences in the rates of complications gastric aspiration in patients who hold vs. continue a single dose of their GLP-1 or GIP agonist medication?

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-08
• Study Start: 2025-08-01
• Study First Submitted: 2025-08-11
• Study First Submitted QC: 2025-08-11
• Last Update Submitted: 2025-08-11
• Study First Posted: 2025-08-17
• Last Update Posted: 2025-08-17
• Primary Completion: 2026-08
• Study Completion: 2026-08-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Adult patient (Age 18 years or older)
• Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy
• Using a GLP-1 or GIP agonist at a stable dose for at least one month

Exclusion Criteria

• Unable to provide informed consent, e.g., dementia

• Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy)

• Risk factors for inadequate bowel preparation besides diabetes and obesity with a likelihood ratio of 1.6 or greater:

  1. Cirrhosis
  2. Parkinson's disease
  3. Dementia
  4. Tricyclic antidepressant use
  5. Opioid use
  6. Gastroparesis* or suspected gastric outlet obstruction on pre-procedure imaging (*defined based on a documented 4-hour solid phase gastric emptying study or prior history of retained gastric contents during upper endoscopy)
  7. Previous colorectal surgery
  8. Prior history of inadequate bowel preparation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Continue GLP/GIP medication	Continue GLP/GIP	Patient maintains dose, frequency, duration of medication prior to colonoscopy.

Primary Outcome Measures

Name	Time	Method
Rate of inadequate bowel preparation	Day of the procedure

Secondary Outcome Measures

Name	Time	Method
Adenoma detection rate	Day of procedure
Median Boston bowel prep score	Day of the procedure
Colonoscope Insertion time	Day of the Procedure	Time it takes to reach the cecum
Total procedure time	Day of the procedure
Rate of unplanned endotracheal intubation	Day of the procedure
Median Ottawa bowel preparation score	Day of the procedure
Withdrawal time	Day of the procedure
hospitalization/emergency department evaluation/readmission for hypoxia or pnemonia within 96 hours after the procedure	From the day of the procedure to 96 hours after the procedure
Other serious adverse events	Day of the procedure up to 96 hours after the procedure.

Trial Locations

Locations (2)

Cleveland Clinic; 🇺🇸 Cleveland, Florida, United States

Cleveland Clinic Weston; 🇺🇸 Weston, Florida, United States